NCT00397579View on ClinicalTrials.gov

DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

July 27, 2017

Study Completion Date

July 27, 2017

Conditions
LeukemiaMyelodysplastic SyndromesBlastic Plasmacytoid Dendritic Cell Neoplasm
Interventions
DRUG

DT388IL3

Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five days.

Trial Locations (1)

75390

UT Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT00397579 - DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter